FreshRecalls

⚠ Data freshness notice: the most recent refresh of NHTSA was incomplete, so a very recent recall may be missing. Everything shown is accurate as of the last checked time on this page — for anything time-critical, confirm with the official sources linked below.

FDAClass II · Drug · Recalled July 1, 2026

Perampanel CIII Tablets recall — SUN PHARMACEUTICAL INDUSTRIES INC

Hazard: Labeling: Label Mix-up: 10mg Perampanel CIII tablet was found in a Perampanel CIII bottle labeled Perampanel 6 mg tablets.

Class II: may cause temporary or medically reversible health consequences.

View the official FDA enforcement record (openFDA) ↗

Official recall ID
D-0628-2026
Brand
SUN PHARMACEUTICAL INDUSTRIES
Classification
Class II
Units affected
3,456 30-count bottles
Recall status
Ongoing
Initiated
Voluntary: Firm initiated

Description

Perampanel CIII Tablets, 6mg, Rx only, 30 Tablets, Mfd.by: Taro Pharmaceutical Industries Ltd., Haifa Bay, Israel 2624761, Dist. by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, NDC 51672-4206-6

Affected products

Companies & origin

Recalling firm location
Princeton, NJ, United States
Firm address
2 Independence Way, N/A, 08540-6620

Identifying details (verbatim from the notice)

Product codes / lots
Lot AE01763, Expires 9/30/2027.
Distribution
Nationwide in the USA
Firm notified the public via
Letter
FDA event ID
99256
Recall initiated
June 17, 2026
FDA classified
June 26, 2026
FDA report date
July 1, 2026

Source: U.S. Food & Drug Administration. This page mirrors the official public-domain record verbatim; the linked government source is authoritative. Source last checked July 23, 2026 at 11:04 PM UTC.

Report a data error on this page